Relay Therapeutics (RLAY) Non-Current Assets (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Non-Current Assets data on file, last reported at $41.2 million in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 31.07% year-over-year to $41.2 million in Q1 2026; TTM through Mar 2026 was $178.6 million, a 29.96% decrease from a year earlier, with the FY2025 full-year figure at $43.1 million, down 30.66% from the prior year.
• Non-Current Assets for Q1 2026 stood at $41.2 million, down from $43.1 million in the prior quarter.
• Over the last five years, Non-Current Assets for RLAY reached as high as $81.4 million in Q3 2022 and fell as low as $33.6 million in Q2 2022.
• Historically, Non-Current Assets has averaged $61.2 million across 5 years, with a median of $65.0 million in 2024.
• Across the five-year window, Non-Current Assets soared 149.27% in 2022 and slumped 31.07% in 2026, its largest moves.
• Year by year, Non-Current Assets stood at $80.3 million in 2022, then retreated by 7.96% to $73.9 million in 2023, then fell by 15.95% to $62.1 million in 2024, then sank by 30.66% to $43.1 million in 2025, then dropped by 4.42% to $41.2 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $41.2 million in Q1 2026, $43.1 million in Q4 2025, and $46.0 million in Q3 2025.